- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02809443
GLS-5700 in Healthy Volunteers
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus.
Zika virus, first discovered in the Zika forest in 1947, has caused a large epidemic in South America, Central America, and the Caribbean islands commencing in late 2014 or early 2015. Zika virus can cause significant neurologic disease to include Guillain Barre Syndrome in adults and microcephaly and other birth defects among children born to mothers who are infected during pregnancy. At present no vaccines or treatments have been approved for Zika virus infection.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada
- CHU de Québec -Université Laval hopital CHUL Centre de Recherche en infectiologie
-
-
-
-
Florida
-
Miami, Florida, United States, 33143
- Miami Research Associate
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- University of Pennslyvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years;
- Able to provide consent to participate and having signed an Informed Consent Form (ICF);
- Able and willing to comply with all study procedures;
- Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is medically unable to induce pregnancy.
- Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or is medically unable to become pregnant;
- Normal screening ECG or screening ECG with no clinically significant findings;
- Screening laboratory must be within normal limits or have only Grade 0-1 findings;
- No history of clinically significant immunosuppressive or autoimmune disease.
- No history of dengue virus vaccination or illness; no history of yellow fever vaccination.
- Dengue seronegative at baseline by screening laboratory evaluation
- Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day).
Exclusion Criteria:
- Administration of an investigational compound either currently or within 30 days of first dose;
- Previous receipt of an investigational product for the treatment or prevention of Zika virus except if participant is verified to have received placebo;
- Administration of any vaccine within 4 weeks of first dose;
- Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose
- Administration of any blood product within 3 months of first dose;
- Pregnancy or breast feeding or plans to become pregnant during the course of the study;
- Positive serologic result for dengue virus (any serotype) or history of receipt of either dengue virus or yellow fever virus vaccination at any time in the past;
- Positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;
- Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response);
- Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater);
- Baseline screening lab(s) with Grade 2 or higher abnormality, except for Grade 2 creatinine;
- Chronic liver disease or cirrhosis;
- Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation;
- Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day);
- Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;
- Prior major surgery or any radiation therapy within 4 weeks of group assignment;
- Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
- Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD)
- Metal implants within 20 cm of the planned site(s) of injection;
- Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.
- Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;
- Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or
- Not willing to allow storage and future use of samples for Zika virus related research
Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GLS-5700 at 1 mg
DNA/dose
|
GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
|
Experimental: GLS-5700 at 2 mg
DNA/dose
|
GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change from baseline in safety laboratory measures
Time Frame: Day 0 through Week 60
|
Day 0 through Week 60
|
Incidence of solicited adverse events after vaccination
Time Frame: Day 0 through Week 60
|
Day 0 through Week 60
|
Incidence of unsolicited adverse events after vaccination
Time Frame: Day 0 through Week 60
|
Day 0 through Week 60
|
Incidence of serious adverse events
Time Frame: Day 0 through Week 60
|
Day 0 through Week 60
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Binding antibody titers to Zika envelope
Time Frame: Day 0 through Week 60 following first dose
|
Day 0 through Week 60 following first dose
|
Neutralizing antibody response against Zika virus
Time Frame: Day 0 through Week 60 following first dose
|
Day 0 through Week 60 following first dose
|
T cell response
Time Frame: Day 0 through Week 60 following first dose
|
Day 0 through Week 60 following first dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Joel Maslow, MD, GeneOne Life Science
Publications and helpful links
General Publications
- Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. N Engl J Med. 2021 Sep 16;385(12):e35. doi: 10.1056/NEJMoa1708120.
- Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med. 2017 Oct 4:10.1056/NEJMoa1708120. doi: 10.1056/NEJMoa1708120. Online ahead of print.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on GLS-5700
-
GeneOne Life Science, Inc.Inovio PharmaceuticalsCompleted
-
GeneOne Life Science, Inc.Active, not recruitingCOVID-19 | HealthyPuerto Rico, United States
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
-
Guangzhou Gloria Biosciences Co., Ltd.Recruiting
-
GeneOne Life Science, Inc.Active, not recruitingSARS-CoV Infection | PneumonitisKorea, Republic of, Puerto Rico, United States, Bulgaria, North Macedonia
-
GeneOne Life Science, Inc.TerminatedSARS-CoV 2 | InfectionUnited States
-
Erchonia CorporationCompleted
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingAdvanced Non-Small Cell Lung CancerChina
-
GeneOne Life Science, Inc.Not yet recruitingSinusitis ChronicUnited States
-
GeneOne Life Science, Inc.Inovio PharmaceuticalsCompleted